Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 13,383 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total value of $419,824.71. Following the transaction, the chief executive officer now owns 295,326 shares in the company, valued at approximately $9,264,376.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Nektar Therapeutics stock traded up $0.68 during mid-day trading on Friday, reaching $32.02. 1,480,671 shares of the company were exchanged, compared to its average volume of 1,752,666. Nektar Therapeutics has a twelve month low of $29.22 and a twelve month high of $92.17. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $5.91 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The company had revenue of $28.22 million during the quarter, compared to analysts’ expectations of $25.45 million. During the same period last year, the firm earned ($0.60) EPS. Equities analysts predict that Nektar Therapeutics will post -3.14 earnings per share for the current year.
A number of research analysts recently issued reports on NKTR shares. Mizuho restated a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a research note on Wednesday, January 23rd. ValuEngine downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 31st. HC Wainwright restated a “hold” rating and set a $47.00 price target on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. BMO Capital Markets started coverage on Nektar Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $75.00 price target on the stock. Finally, TheStreet upgraded Nektar Therapeutics from a “d+” rating to a “c” rating in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and an average price target of $69.73.
A number of institutional investors have recently bought and sold shares of NKTR. Wellington Management Group LLP lifted its position in Nektar Therapeutics by 20.7% during the 1st quarter. Wellington Management Group LLP now owns 12,961,558 shares of the biopharmaceutical company’s stock worth $435,507,000 after acquiring an additional 2,220,193 shares during the period. FMR LLC lifted its position in Nektar Therapeutics by 8.5% during the 4th quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock worth $853,355,000 after acquiring an additional 2,041,954 shares during the period. Norges Bank acquired a new stake in Nektar Therapeutics during the 4th quarter worth approximately $63,723,000. Vanguard Group Inc lifted its holdings in shares of Nektar Therapeutics by 3.6% in the 3rd quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock valued at $1,153,525,000 after buying an additional 660,907 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Nektar Therapeutics by 131.6% in the 4th quarter. Deutsche Bank AG now owns 947,004 shares of the biopharmaceutical company’s stock valued at $31,125,000 after buying an additional 538,170 shares during the period. 94.90% of the stock is owned by institutional investors.
WARNING: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.americanbankingnews.com/2019/05/17/insider-selling-nektar-therapeutics-nktr-ceo-sells-13383-shares-of-stock.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Article: Risk Tolerance
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.